Publication | Closed Access

Leuconostoc mesenteroides-derived anticancer pharmaceuticals hinder inflammation and cell survival in colon cancer cells by modulating NF-κB/AKT/PTEN/MAPK pathways

InflammationAnti-inflammatoryOncologyMedicineColon Cancer CellsImmunologyTumor ImmunityCancer Cell BiologyCancer BiologyImmunotherapeuticsNf-κb/akt/pten/mapk PathwaysAnti-cancer AgentPharmacologyCancer ResearchCell SurvivalTumor Biology